TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25521772

Group type: EXPERIMENTAL
Intervention: Coping and communication intervention
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Supportive counseling intervention
Number of subjects: 173
Study: 24428912

Group type: EXPERIMENTAL
Intervention: PAHC questionnaire with feedback to genetic counselor
Number of subjects: 264

Group type: COMPARATOR
Intervention: PAHC questionnaire without feedback to genetic counselor
Number of subjects: 264
Study: 22328549

Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm (aVSP) severity graded as none, mild, moderate, or severe
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm (aVSP) severity
Number of subjects: 409
Study: 19681414

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg (Group R1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg/kg (Group R2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo saline (Group S)
Number of subjects: 32
Study: 18078072

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (SelenoPRECISE, 200 microg daily for 16 weeks)
Number of subjects: 20
Study: 15467529

Group type: EXPERIMENTAL
Intervention: 2-hour intervention class on infant care and breastfeeding promotion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Class on infant care only (control group)
Number of subjects: 59
Study: 16779740

Group type: EXPERIMENTAL
Intervention: aP vaccine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 2
Study: 10367588

Group type: EXPERIMENTAL
Intervention: xamoterol, 200 mg (beta1‐adrenoceptor partial agonist)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: prenalterol, 50 mg (beta1‐ and beta2‐adrenoceptor partial agonist)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: salbutamol, 8 mg (beta2‐adrenoceptor partial agonist)
Number of subjects: 8

Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg (selective beta2‐adrenoceptor antagonist)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of partial agonists with ICI 118,551
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8891938

Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) application
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tetracycline HCI (TTC) root conditioning only
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 11
Study: 1900381

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control (no IABP)
Number of subjects: 810
Study: 6510016

Group type: EXPERIMENTAL
Intervention: Slow-release indomethacin (50 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Diflunisal (250 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 44
Study: 30536189

Group type: EXPERIMENTAL
Intervention: Parent-youth (PY) intervention
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Parent-only (PO) intervention
Number of subjects: 532

Group type: COMPARATOR
Intervention: Comparison (C) group
Number of subjects: 532
Study: 28382785

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Readymade growth factors
Number of subjects: 20
Study: 26811165

Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 24
Study: 25139609

Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring (CGM)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Frequent point-of-care (POC) measurement
Number of subjects: 87
Study: 22495074

Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 402
Study: 19384120

Group type: EXPERIMENTAL
Intervention: Paracervical lidocaine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Intracervical lidocaine
Number of subjects: 132
Study: 17240221

Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception (EC)
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Direct pharmacy access to emergency contraception (EC)
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Clinic access to emergency contraception (EC)
Number of subjects: 1950
Study: 15695981

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate
Number of subjects: 50
Study: 12148711

Group type: EXPERIMENTAL
Intervention: Clinical pharmacy services
Number of subjects: 23
Study: 9808807

Group type: EXPERIMENTAL
Intervention: Stage-Matched Materials
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Standard Materials
Number of subjects: 1864

Group type: COMPARATOR
Intervention: No Educational Materials
Number of subjects: 1864
Study: 8704420

Group type: EXPERIMENTAL
Intervention: Bushen Kangkui Decoction (BSKKD)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Injectio cimetidine
Number of subjects: 150
Study: 30489324

Group type: EXPERIMENTAL
Intervention: Postoperative compliance surveillance and prompting strategy directed toward the care team
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 29075507

Group type: EXPERIMENTAL
Intervention: Dermatuff™ knee-length socks containing Kevlar fibres worn for 16 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sock wearing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quality of life measured by EQ5D5L
Number of subjects: 90
Study: 25261090

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SMT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham spinal manipulation (sham-SMT)
Number of subjects: 56
Study: 23325373

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22021700

Group type: EXPERIMENTAL
Intervention: Citalopram (2 ml intravenously)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (2 ml of 0.9% NaCl intravenously)
Number of subjects: 6
Study: 19692881

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g) administered after intubation before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (100 mL 0.9% NaCl infused intravenously)
Number of subjects: 40
Study: 16478839

Group type: EXPERIMENTAL
Intervention: Group C: Prior scheduled appointment
Number of subjects: 384

Group type: COMPARATOR
Intervention: Group A: Usual discharge care
Number of subjects: 384

Group type: COMPARATOR
Intervention: Group B: Free prednisone and transport vouchers with telephone reminder
Number of subjects: 384

Group type: COMPARATOR
Intervention: Group A, B, C
Number of subjects: 384
Study: 14964347

Group type: EXPERIMENTAL
Intervention: Master Amino Acid Pattern (MAP®) as a sole and total substitute of dietary proteins
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: MAP in conjunction with ANC/OMP
Number of subjects: 500
Study: 11103054

Group type: EXPERIMENTAL
Intervention: Epoetin alfa high-dose (40,000 U)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Epoetin alfa low-dose (20,000 U)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 9263612

Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg T.I.D. at meals) plus 1 g oral calcium daily
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo plus 1 g oral calcium daily
Number of subjects: 453
Study: 8518909

Group type: EXPERIMENTAL
Intervention: Division of the superior rectal artery
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Complete rectal mobilization to the pelvic floor
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Completion of anastomosis (both techniques)
Number of subjects: 24
Study: 3440813

Group type: EXPERIMENTAL
Intervention: Exercise for 30 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest for 30 min
Number of subjects: 20
Study: 28704254

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 178
Study: 27125531

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control
Number of subjects: 155
Study: 24525635

Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg/d) + Citalopram (20 to 60 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Citalopram (20 to 60 mg/d) + Placebo
Number of subjects: 40
Study: 23298508

Group type: EXPERIMENTAL
Intervention: Serenoa repens 320 mg every day for 24 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Finasteride 1 mg every day for 24 months
Number of subjects: 100
Study: 20399899

Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (CS) 800 mg daily for 3 months
Number of subjects: 129
Study: 19478343

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea extract, 100 mg twice daily for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea extract
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15904630

Group type: EXPERIMENTAL
Intervention: Omapatrilat 80 mg/day
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 12683707

Group type: EXPERIMENTAL
Intervention: Domiciliary pulmonary rehabilitation program (walking, breathing exercises, postural drainage, controlled coughing, lifestyle changes) for 30 minutes twice daily for four weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 10613426

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 days, 20 g x d(‐1))
Number of subjects: 10
Study: 7557824

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (CBS) 240 mg bid for 4-8 weeks, followed by placebo maintenance treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (CBS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 53
Study: 1940120

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 0
Study: 6266576

Group type: EXPERIMENTAL
Intervention: MK-421 20 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MK-421 5 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30793860

Group type: EXPERIMENTAL
Intervention: Silicone adhesive dressings with standard preventive care
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (standard preventive care only)
Number of subjects: 71
Study: 30080086

Group type: EXPERIMENTAL
Intervention: SOSA support group
Number of subjects: 92
Study: 27776081

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24582842

Group type: EXPERIMENTAL
Intervention: Free wrist motion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Splinted wrist motion (blocking radial and ulnar deviation)
Number of subjects: 10
Study: 22985672

Group type: EXPERIMENTAL
Intervention: 50 mg oral DHEA for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0
Study: 20179296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 3600
Study: 16930802

Group type: EXPERIMENTAL
Intervention: L-Theanine at the start of the experimental procedure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-Theanine midway through the experimental procedure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nothing (control)
Number of subjects: 12
Study: 16421692

Group type: EXPERIMENTAL
Intervention: Dual defibrillator (group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard DDD pacing (group B)
Number of subjects: 63
Study: 11879259

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (dose range 25‐100 mg)
Number of subjects: 2077
Study: 10999086

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) 7.5 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) 10 mg/kg
Number of subjects: 58
Study: 7474755

Group type: EXPERIMENTAL
Intervention: End-to-side anastomoses (Group A, 60 patients)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: End-to-end anastomoses (Group B, 40 patients)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: End-to-end and end-to-side anastomoses (Group C, 50 patients)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (Group O, 30 patients)
Number of subjects: 150
Study: 2174575

Group type: EXPERIMENTAL
Intervention: Oil-based contrast medium (OBCM)
Number of subjects: 40
Study: 6943331

Group type: COMPARATOR
Intervention: Extracoronal wire ligation (Group I)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Composite restorative material (Group II)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and II)
Number of subjects: 18
Study: 28488825

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (2 sessions per week, 45-60 minutes each for 12 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aquatic exercise program
Number of subjects: 36
Study: 27212617

Group type: EXPERIMENTAL
Intervention: Higher protein formula (n=550)
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Lower protein formula (n=540)
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Observational group (exclusively breastfed for at least three months, n=588)
Number of subjects: 1678
Study: 24693973

Group type: EXPERIMENTAL
Intervention: Advanced oxidation protein products (AOPP) levels measured at 2.5, 5.5, 10.5, 15 and 24 months of age.
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Cluster membership based on AOPP levels (Group A: lower AOPP levels, Group B: higher AOPP levels).
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms GCLC RS10948751 and HMOX1 RS17885925.
Number of subjects: 312
Study: 23229858

Group type: EXPERIMENTAL
Intervention: Cilobradine 0.25-5 mg doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19902278

Group type: EXPERIMENTAL
Intervention: Intraseptal anaesthesia (ISA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Periodontal ligament anaesthesia (PLA)
Number of subjects: 35
Study: 18763638

Group type: EXPERIMENTAL
Intervention: Grape procyanidins (GPC) 100 mg/day for 60 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Starch capsule (control)
Number of subjects: 60
Study: 17182445

Group type: EXPERIMENTAL
Intervention: Cocaine pharmacotherapy
Number of subjects: 402
Study: 12819312

Group type: EXPERIMENTAL
Intervention: Lifestyle-modification program (goals: at least 7% weight loss and at least 150 min of physical activity per week)
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study: 10874895

Group type: EXPERIMENTAL
Intervention: Subcutaneous r-hirudin (25 mg twice daily)
Number of subjects: 19
Study: 9378876

Group type: EXPERIMENTAL
Intervention: Peppermint oil (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 1551969

Group type: EXPERIMENTAL
Intervention: 40 mg/day prednisolone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3925176

Group type: EXPERIMENTAL
Intervention: Tubing changes every 2 days (Group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tubing changes every 4 days (Group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Historic series (comparison)
Number of subjects: 52
Study: 30366601

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 29448382

Group type: EXPERIMENTAL
Intervention: Double-edge swap (degree-preserving randomization of the configuration model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single edge replacement (full randomization of the Erdős‐Rényi random graph)
Number of subjects: 0
Study: 27741192

Group type: EXPERIMENTAL
Intervention: Intra-fetal digoxin (1.0 mg)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Intra-amniotic digoxin (1.0 mg)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 270
Study: 24549168

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme including supervised exercise sessions and information sessions
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 78
Study: 23027880

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower baseline EDSS scores
Number of subjects: 0
Study: 20403733

Group type: EXPERIMENTAL
Intervention: Thermoneutral water immersion (TWI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study: 18686816

Group type: EXPERIMENTAL
Intervention: Arthroscopic treatment for knee OA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic techniques in special subgroups (acute pain exacerbation, mechanical block, early OA)
Number of subjects: 0
Study: 16025963

Group type: EXPERIMENTAL
Intervention: Kebimin decoction (KD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Xinfang rhinitis capsule (Control)
Number of subjects: 60
Study: 14606735

Group type: EXPERIMENTAL
Intervention: Education and counselling intervention (stroke information package and three visits from a social worker trained in family counselling)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Education and counselling intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62
Study: 10591669

Group type: EXPERIMENTAL
Intervention: Folic acid 2.4 mg/d (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Folic acid 0.4 mg/d (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Folic acid 0.0 mg/d (group 3)
Number of subjects: 60
Study: 8672762

Group type: EXPERIMENTAL
Intervention: 5 or 10 MU/day natural interferon‐α (IFNα) for 38 weeks
Number of subjects: 57
Study: 1987744

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (IFN-alpha-N1) combined with cyclophosphamide, doxorubicin, and cisplatin (CAP regimen)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (IFN-alpha-N1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Multiagent chemotherapy regimen of CAP
Number of subjects: 14
Study: 6398833

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxamniquine (15 mg/kg)
Number of subjects: 0
Study: 31752815

Group type: EXPERIMENTAL
Intervention: en_línea
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: standard group therapy
Number of subjects: 305

Group type: COMPARATOR
Intervention: control group
Number of subjects: 305
Study: 30183582

Group type: EXPERIMENTAL
Intervention: 80% oxygen during surgery
Number of subjects: 1386

Group type: COMPARATOR
Intervention: 30% oxygen during surgery
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Hyperthermia
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Both hypothermia and emergency surgery
Number of subjects: 1386
Study: 26926320

Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Meeting guidelines for all health behaviors
Number of subjects: 204

Group type: COMPARATOR
Intervention: Baseline health behaviors
Number of subjects: 204
Study: 23317480

Group type: EXPERIMENTAL
Intervention: Elaborated VF (VF plus cognitive preparation and cognitive review)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Standard VF (VF plus cognitive preparation)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No VF (exposure alone)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Elaborated VF
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Standard VF
Number of subjects: 68
Study: 23031172

Group type: EXPERIMENTAL
Intervention: FES‐assisted walking
Number of subjects: 34

Group type: COMPARATOR
Intervention: Aerobic and resistance training (control)
Number of subjects: 34
Study: 19733449

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 67

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67
Study: 22978725

Group type: EXPERIMENTAL
Intervention: REA‐ICU index
Number of subjects: 850

Group type: COMPARATOR
Intervention: Pneumonia severity assessment tools (PSI and CURB‐65)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Alternate clinical prediction models (SMART‐COP, CURXO‐80, and the 2007 IDSA/ATS minor severity criteria)
Number of subjects: 850
Study: 16187232

Group type: EXPERIMENTAL
Intervention: Immunotherapy (aPBSC transplant with IL-2 incubation for 24 hours followed by parenteral IL-2 for 5 days, then 2 days of rest for 4 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No immunotherapy (aPBSC transplant without immunotherapy)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: No immunotherapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Patients developing acute graft versus host disease (aGVHD)
Number of subjects: 59
Study: 12598277

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (150 microg) + incision site bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epidural placebo + incision site bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo + incision site saline
Number of subjects: 120